Schering building diabetes presence de Novo: Prandin and insulin co-promotions with Novo Nordisk.
Executive Summary
SCHERING ENTERING DIABETES MARKET VIA NOVO PRANDIN, INSULIN LINE copromotion agreement announced by the two firms Jan. 28. The two companies signed a multi-year agreement to copromote Novo Nordisk's recently approved type 2 diabetes agent Prandin (repaglinide), along with Novo's full range of insulin products and devices. Prandin was approved Dec. 22 for oral treatment of type 2 diabetes as monotherapy or in combination with Bristol-Myers Squibb's Glucophage (metformin). At that time, Novo said that it would launch the product in the spring after finding a marketing partner ("The Pink Sheet" Jan. 5, p. 15).